Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. - Wikidata - wikimedia - TriplyDB

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.

http://www.wikidata.org/entity/Q39519148

about

Parallel visualization of multiple protein complexes in individual cells in tumor tissue Advanced gastric cancer: Current treatment landscape and future perspectives Changing strategies for target therapy in gastric cancer Gastric Cancer: New Drugs - New Strategies Molecular targeted therapy for the treatment of gastric cancer The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond Clinical impact of tumour biology in the management of gastroesophageal cancer A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer Recent advances in the HER2 targeted therapy of gastric cancer A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells.Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer.A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.Targeted therapy in gastroesophageal cancers: past, present and future.Targeted therapies in gastric cancer and future perspectives.Gastric cancer and trastuzumab: first biologic therapy in gastric cancer.Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population.Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review).Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?Helicobacter pylori: gastric cancer and extragastric malignancies - clinical aspects.Biomarkers of drugs targeting HER-family signalling in cancer.HER2 therapies and gastric cancer: a step forward.The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.HER2 directed therapy for gastric/esophageal cancers.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Investigational therapies targeting the ErbB family in oesophagogastric cancer.Clinical management of advanced gastric cancer: the role of new molecular drugs.Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.Pertuzumab in gastrointestinal cancer.

P2860

Q24320208-55146493-FFF3-4506-83C6-195350188F4C Q26764934-958223CA-0D5D-4182-8237-0B327DE33602 Q26774513-54708DF2-90D5-485F-A9F1-998A7EE9D7CA Q27028079-5DAB5887-E062-4BF2-B98C-F44EC55DA4A0 Q28072433-02BC13F0-6708-43DB-977D-C7AE8DF9F88E Q28078788-EE8D7D57-BA33-487B-B550-797691AE03A0 Q33922534-9C378508-8033-46A6-A42C-389417790B66 Q34051972-43E9F2C4-55FA-4AF1-BF9A-AD60CBA3052F Q34967104-8FE25968-4C74-43C1-8057-6A3E8756AA2C Q35052987-EEAA5B49-A1CB-4811-89CE-9616CC0943E8 Q35119526-03CC115C-0BC3-47E8-B0BD-099C52EDC994 Q35199371-B2A60D89-0A3A-42A8-98C1-6CEF471090AA Q35948050-056DF2A2-8FDB-4933-83F8-B57B35C5F2C1 Q36294579-08D92484-6180-4F90-93C9-A642F7803596 Q36471685-DA34AA63-E13C-4F8D-BEF5-B3CDDD140480 Q36567393-D955E9F7-750E-4D64-8BF1-176ACA19D34B Q36897947-723ABAA6-68E9-4049-9549-EA6B4A7601A2 Q37046550-D26F47FB-DA1E-424D-8A35-277DD0EE22C2 Q37241496-30B2B52A-01AA-4A0A-B215-BB064787851F Q37308782-7FDB2DA6-E726-4F3D-94AE-547663C775AD Q37468304-CE17902E-2160-4F91-96C9-1AA19FF245CA Q37567784-228B0070-8650-4622-8937-7E1DF5BEB013 Q37703226-2D59FB41-D85E-4E5A-A7A6-019C9CE7103F Q37708897-B5473C00-722A-4892-9D1D-2BCA2F9B40B3 Q37724647-963350B1-AECC-40C3-921D-8D62F4FC7B0B Q38073827-68946021-8867-425A-A5DF-63BB07D2B6D1 Q38074157-013E12CF-F321-47A5-958F-93D113C7BD51 Q38134872-ED2EB42F-C5AB-4AAD-A5AC-2B8E9BC9C72E Q38150774-D5A944D9-75D3-4A0F-B592-131B06AFC611 Q38151672-11E8F60A-3C24-4601-81E2-CAF012B9E2C8 Q38177325-429AECFD-2547-422A-8A55-129C545252A2 Q38210070-9FDFFB69-3A6D-47A0-BC9C-7699E44D83FE Q38210387-B1F29861-3FC1-413F-869D-9211721C21D0 Q38214511-72F33B43-2E3B-4D4A-93FE-48717A2BC84D Q38221886-15CA936B-86AF-42B6-BFCE-49E65FFCFD70 Q38263841-DFC31E86-68BB-4EFA-AE29-08BCD5344718 Q38390565-3E560A9C-10E3-4650-983C-D5A2462FB720 Q38392935-F0BB1741-4C17-4CE7-9B34-2B96F25AB382 Q38451287-0A68D8A9-3404-43C6-8F0C-D2DFECFDEA95 Q38653309-778A9EB3-0359-4255-9FB4-E24B1E5B8F8C

P2860

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.

http://www.wikidata.org/entity/Q39519148

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Pertuzumab in combination with ...... stric cancer xenograft models.

@en

Pertuzumab in combination with ...... stric cancer xenograft models.

@nl

type

label

Pertuzumab in combination with ...... stric cancer xenograft models.

@en

Pertuzumab in combination with ...... stric cancer xenograft models.

@nl

prefLabel

Pertuzumab in combination with ...... stric cancer xenograft models.

@en

Pertuzumab in combination with ...... stric cancer xenograft models.

@nl

P1433

Q39519148-CCD58484-C39B-445F-A84B-FB55D384FEC8

P1476

Q39519148-74C309BC-70A1-4187-A116-DE9C3897DA4A

P2093

Q39519148-72DFBEBE-58E4-467D-B426-8E42622A3884

Q39519148-7B28D334-2469-4EEC-8AA1-C5FA63870B73

Q39519148-806B5760-8927-4C9D-AEC2-C54AEFD6F4DE

Q39519148-9983E8A2-D73A-4E07-9520-654DA7678EDE

Q39519148-AB13B2A6-32EE-4894-AEBB-E0DAE4653C33

Q39519148-CFFBA311-8728-4209-A618-0DC9C510E31E

Q39519148-E7E3B49E-28FE-4EAA-96D3-82233F8D193A

P304

Q39519148-8D254374-19FA-4561-8CCC-20CED9A93F02

P31

Q39519148-81F9F14D-4F4E-47BE-AE3E-F39ACD7CB2CE

P356

Q39519148-C2658E29-B9A2-457E-90DD-F680F7DAF1EA

P407

Q39519148-7F551CFD-7CCF-4568-A7FD-B47FA271FE45

P433

Q39519148-9870D64D-D599-45BC-8BAA-4FF1F6551709

P478

Q39519148-0FEB0169-7F08-4B87-BDCE-C78B0A68AA5F

P577

Q39519148-5BFE7008-2905-4E17-AF9E-145548F76912

P698

Q39519148-CFEE1D9B-6C04-41D7-808B-3FB30D2FF88F

P921

Q39519148-271E99AE-ACAF-4234-9171-96F407E1123D

P356

1078-0432.CCR-10-2927

P1433

Clinical Cancer Research

P1476

Pertuzumab in combination with ...... stric cancer xenograft models.

@en

P2093

Kaori Fujimoto-Ouchi

http://www.w3.org/2001/XMLSchema#string

Keigo Yorozu

http://www.w3.org/2001/XMLSchema#string

Koh Furugaki

http://www.w3.org/2001/XMLSchema#string

Masateru Ohta

http://www.w3.org/2001/XMLSchema#string

Mitsue Kurasawa

http://www.w3.org/2001/XMLSchema#string

Shigeyuki Iijima

http://www.w3.org/2001/XMLSchema#string

Yoriko Yamashita-Kashima

http://www.w3.org/2001/XMLSchema#string

P304

5060-5070

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-2927

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21700765

http://www.w3.org/2001/XMLSchema#string

P921